Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HRD Positive Advanced Breast Cancer”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06254066
What this trial is testing

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Who this might be right for
Female Breast Cancer PatientsHistopathologically Confirmed Advanced HR +/HER2-invasive Breast CancerHRD Positive Advanced Breast Cancer
Zhejiang Cancer Hospital 40
Testing effectiveness (Phase 2)Ended earlyNCT06065059
What this trial is testing

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Who this might be right for
Breast CancerOvarian CancerPancreas Cancer+5 more
Tango Therapeutics, Inc. 7
Testing effectiveness (Phase 2)UnknownNCT05085626
What this trial is testing

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced HER2 Negative Breast CarcinomaHRD+Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 40
Large-scale testing (Phase 3)Looking for participantsNCT06255392
What this trial is testing

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Who this might be right for
Fludzoparib" and Anti-angiogenicHRD-positive/HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 200
Large-scale testing (Phase 3)Active Not RecruitingNCT07371910
What this trial is testing

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Metastatic Breast CancerHRD-Positive/HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 200